On November 12, 2024, In8bio, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the third quarter ending September 30, 2024. The company, which specializes in developing gamma-delta T cell therapies for cancer, reported a net loss of $7.1 million, or $0.15 per share, a slight improvement from the $7.2 million loss in the previous year. Research and Development expenses decreased to $3.3 million from $3.8 million due to workforce reductions and a strategic focus on pipeline prioritization. General and Administrative expenses also saw a reduction to $2.7 million from $3.4 million. The company completed a private placement in October 2024, securing net proceeds of $11.6 million, extending its cash runway through the first quarter of 2026. In8bio highlighted the continued remission of all Acute Myeloid Leukemia patients treated with their INB-100 therapy...Show More

On November 12, 2024, In8bio, Inc., a clinical-stage biopharmaceutical company, announced its financial results for the third quarter ending September 30, 2024. The company, which specializes in developing gamma-delta T cell therapies for cancer, reported a net loss of $7.1 million, or $0.15 per share, a slight improvement from the $7.2 million loss in the previous year. Research and Development expenses decreased to $3.3 million from $3.8 million due to workforce reductions and a strategic focus on pipeline prioritization. General and Administrative expenses also saw a reduction to $2.7 million from $3.4 million. The company completed a private placement in October 2024, securing net proceeds of $11.6 million, extending its cash runway through the first quarter of 2026. In8bio highlighted the continued remission of all Acute Myeloid Leukemia patients treated with their INB-100 therapy and announced plans to expand the trial. The company also presented updated clinical trial results and received FDA guidance for a future registrational trial of INB-100. Despite suspending enrollment in its Phase 2 clinical trial for glioblastoma, In8bio will continue to monitor previously treated patients. The company's strategic realignment aims to enhance its capacity to deliver on the potential of gamma-delta T cell therapies.